An increase in the in vivo binding of [3H]SCH 23390 induced by MK-801 in the mouse striatum

This publication has 15 references indexed in Scilit:

• The effect of benzodiazepines on the binding of [3H]SCH 23390 in vivo
  Neuropharmacology, 1992
• Reserpine-induced reduction of in vivo binding of SCH 23390 and N-methylspiperone and its reveral by d-amphetamine
  European Journal of Pharmacology, 1991
• MK-801 potentiates dopaminergic D1 but reduces D2 responses in the 6-hydroxydopamine model of Parkinson's disease
  European Journal of Pharmacology, 1990
• Interactions between glutamatergic and monoaminergic systems within the basal ganglia-implications for schizophrenia and Parkinson's disease
  Trends in Neurosciences, 1990
• The NMDA antagonist MK-801 causes marked locomotor stimulation in monoamine-depleted mice
  Journal Of Neural Transmission-Parkinsons Disease and Dementia Section, 1989
• Blockade of “reverse tolerance” to cocaine and amphetamine by MK-801
  Life Sciences, 1989
• The current status of the dopamine hypothesis of schizophrenia
  Neuropsychopharmacology, 1988
• Stereospecific binding of a new benzazepine, [³H]SCH23390, in cortex and neostriatum
  Canadian Journal of Physiology and Pharmacology, 1987
• Specific binding of 3H-SCH 23390 to dopamine D1 receptors
  Life Sciences, 1986
• A quantitative model for the in vivo assessment of drug binding sites with positron emission tomography
  Annals of Neurology, 1984